Wall Street analyst estimates for Boston Scientific Corporation (BSX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
Consensus price target
$54.65 (+30 % vs price $41.98)
between $46.00 and $71.00 · 16 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $21.0B | $21.0B – $21.1B | $3.18 | 16 |
| 2027E | $21.0B | $20.4B – $23.0B | $3.17 | 17 |
| 2028E | $22.2B | $21.4B – $24.6B | $3.40 | 10 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 36 |
| Hold | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 44 |
| Avg rating (−2 sell to +2 buy) | 0.86 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-03 | $0.79 | ||
| 2026-10-28 | $0.73 | $0.73 | +0.4% |
| 2026-07-29 | $0.86 | $0.83 | +3.0% |
| 2026-04-22 | $0.80 | $0.79 | +1.5% |
| 2026-02-04 | $0.80 | $0.78 | +2.4% |
| 2025-10-22 | $0.75 | $0.71 | +5.0% |
| 2025-07-23 | $0.75 | $0.72 | +3.4% |
| 2025-04-23 | $0.75 | $0.67 | +11.4% |
Valuation Ratios
| P/E Ratio | 17.79 |
| Price / Book | 2.44 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.39B | $9.05B | $9.82B | $10.73B | $9.91B | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B |
| Cost of Revenue | $3.04B | $3.18B | $3.35B | $3.86B | $4.34B | $4.43B | $4.97B | $5.41B | $6.48B | $6.22B |
| Gross Profit | $5.34B | $5.87B | $6.48B | $6.88B | $5.58B | $7.46B | $7.71B | $8.83B | $10.27B | $13.85B |
| Research & Development | $920.0M | $997.0M | $1.11B | $1.17B | $1.14B | $1.20B | $1.32B | $1.41B | $1.61B | $2.05B |
| Selling, General & Admin | $3.08B | $3.28B | $3.56B | $3.93B | $3.79B | $4.29B | $4.52B | $5.19B | $5.98B | $6.89B |
| Operating Expenses | $4.11B | $4.35B | $4.74B | $5.17B | $4.97B | $5.54B | $5.89B | $6.65B | $7.63B | $9.88B |
| Operating Income | $1.24B | $1.52B | $1.74B | $1.71B | $601.0M | $1.92B | $1.82B | $2.18B | $2.63B | $3.97B |
| EBITDA | $1.23B | $2.01B | $2.58B | $2.21B | $1.51B | $2.52B | $2.74B | $3.45B | $3.94B | $5.10B |
| Interest Expense | $234.0M | $230.0M | $269.0M | $513.0M | $468.0M | $349.0M | $464.0M | $272.0M | $387.0M | $349.0M |
| Pre-tax Income | $177.0M | $933.0M | $1.42B | $687.0M | -$79.0M | $1.08B | $1.14B | $1.99B | $2.28B | $3.38B |
| Income Tax | -$170.0M | $828.0M | -$249.0M | -$4.01B | $2.0M | $36.0M | $443.0M | $393.0M | $436.0M | $493.0M |
| Net Income | $347.0M | $104.0M | $1.67B | $4.70B | -$82.0M | $1.04B | $698.0M | $1.59B | $1.85B | $2.89B |
| EPS | $0.26 | $0.08 | $1.21 | $3.38 | -$0.08 | $0.69 | $0.45 | $1.08 | $1.26 | $1.96 |
| EPS (Diluted) | $0.25 | $0.07 | $1.19 | $3.33 | -$0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
| Shares Outstanding (Diluted) | 1,377.2 M | 1,392.7 M | 1,401.4 M | 1,410.6 M | 1,416.7 M | 1,433.8 M | 1,439.7 M | 1,463.5 M | 1,485.9 M | 1,494.5 M |
Price
| Price | $41.98 (closing price, October 30, 2026) |
| Market Cap | $60.8B |
| Exchange | NYSE |
| Country | US |
Related companies: MMSI · LIVN · ATRC · MDT · EW · PEN · TFX
Explore sector: Healthcare · Medical - Devices
More sections of BSX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks